The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models

Wenyu Hu(Xijing Hospital), Nanlin Li(Xijing Hospital)

Breast Cancer Targets and Therapy

December 1, 2023

10.2147/bctt.s434973

Cited by 4

Related Papers

HGH1 Promotes Breast Cancer Progression Through the PI3K/AKT/NF-κB Signaling Pathway: Potential Role for Prognosis and Targeted Therapy

|Breast Cancer Targets and Therapy|2025|2

Abstract PO1-27-01: Comparing the Efficacy and Safety of TQB2440 versus the Reference Pertuzumab for the Treatment of HER2-Positive Early or Locally Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase 3 Trial

|Cancer Research|2024|0